- Stocks
- Healthcare
- NASDAQ: DXCM

Price (delayed)

$411

Market cap

$39.35B

P/E Ratio

184.3

Dividend/share

N/A

EPS

$2.23

Enterprise value

$40.57B

The company's equity has surged by 97% YoY and by 45% QoQ

DXCM's gross profit is up by 43% year-on-year and by 8% since the previous quarter

The debt has soared by 61% YoY and by 50% from the previous quarter

What are the main financial stats of DXCM

Market
Valuations
Earnings

Shares outstanding

95.74M

Market cap

$39.35B

Enterprise value

$40.57B

Price to earnings (P/E)

184.3

Price to book (P/B)

28.03

Price to sales (P/S)

22.47

EV/EBIT

147.63

EV/EBITDA

122.82

EV/Sales

23.64

Revenue

$1.72B

EBIT

$274.8M

EBITDA

$330.3M

Free cash flow

$209M

Per share
Balance sheet
Liquidity

EPS

$2.23

Free cash flow per share

$2.23

Book value per share

$14.66

Revenue per share

$18.29

TBVPS

$37.35

Total assets

$3.52B

Total liabilities

$2.17B

Debt

$1.75B

Equity

$1.35B

Working capital

$2.63B

Debt to equity

1.29

Current ratio

7.58

Quick ratio

7.01

Net debt/EBITDA

3.69

Margins
Efficiency
Dividend

EBITDA margin

19.2%

Gross margin

63.9%

Net margin

11.9%

Operating margin

15.1%

Return on assets

7.8%

Return on equity

20.8%

Return on invested capital

9%

Return on capital employed

8.8%

Return on sales

16%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Dexcom stock price performed over time

How have Dexcom's revenue and profit performed over time

Revenue

$1.72B

Gross profit

$1.1B

Operating income

$258.9M

Net income

$204.7M

Gross margin

63.9%

Net margin

11.9%

The net margin has soared by 185% YoY and by 29% from the previous quarter

DXCM's gross profit is up by 43% year-on-year and by 8% since the previous quarter

Dexcom's revenue has increased by 40% YoY and by 7% from the previous quarter

Dexcom's net income has increased by 38% from the previous quarter

What is Dexcom's growth rate over time

What is Dexcom stock price valuation

P/E

184.3

P/B

28.03

P/S

22.47

EV/EBIT

147.63

EV/EBITDA

122.82

EV/Sales

23.64

The EPS rose by 38% QoQ

The company's equity has surged by 97% YoY and by 45% QoQ

DXCM's P/B is 35% above its 5-year quarterly average of 20.8 and 19% above its last 4 quarters average of 23.6

The stock's price to sales (P/S) is 90% more than its 5-year quarterly average of 11.8 and 47% more than its last 4 quarters average of 15.3

Dexcom's revenue has increased by 40% YoY and by 7% from the previous quarter

How efficient is Dexcom business performance

Dexcom's ROA has soared by 181% YoY and by 20% from the previous quarter

The ROE has soared by 179% year-on-year and by 15% since the previous quarter

The ROS rose by 19% QoQ

DXCM's return on invested capital is up by 6% since the previous quarter

What is DXCM's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DXCM.

How did Dexcom financials performed over time

The company's total assets is 62% higher than its total liabilities

The company's total assets has surged by 70% YoY and by 44% QoQ

The total liabilities has surged by 57% year-on-year and by 43% since the previous quarter

The debt is 29% more than the equity

The company's equity has surged by 97% YoY and by 45% QoQ

The debt has soared by 61% YoY and by 50% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.